Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment

Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment Stefan Sleijfer, Erik Wiemer, Caroline Seynaeve, Jaap Verweij Oncologist 2007; 12: 719-726 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in sarcomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Describe the most important resistance mechanisms to imatinib that are responsible for early and late progression. Discuss the most important systemic treatment options for managing progressive disease under imatinib treatment. Explain how insight into mechanisms conferring sensitivity to imatinib may be used to individualize treatment of patients presenting with GIST. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jun. 29, 2007 Most Recent Review: Jun. 29, 2007* Most Recent Update: Jun. 29, 2007 Date Credit Expires: Jun. 29, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course